Results 91 to 100 of about 4,315,874 (223)

Efficacy and safety of high doses of eltrombopag for treating adult immune thrombocytopenia: Results from a multicentre retrospective cohort study

British Journal of Haematology, EarlyView.
Salomé Dahan, Stéphanie Guillet, Olivier Fain, Delphine Gobert, Stéphane Cheze, Florent Broca, Bertrand Godeau, Marc Michel   +7 more
wiley   +1 more source

The lymphocyte function of allogeneic peripheral blood stem cell grafts is associated with relapse and cytomegalovirus reactivation

Transfusion, EarlyView.
Abstract Background Allogeneic hematopoietic stem cell transplantation (HSCT) is a treatment primarily for hematological malignancies. Infections, relapse, and graft versus host disease (GvHD) are some of the most common adverse events following HSCT. We aimed to evaluate whether the lymphocyte function of the stem cell graft was associated with these ...
Anna Söderström, Tengyu Wang, Johan Törlén, Hannes Lindahl, Davide Valentini, Stephan Mielke, Klara Asplund Högelin, Rebecca Axelsson Robertson, Michael Uhlin   +8 more
wiley   +1 more source

Primary myelofibrosis: spectrum of imaging features and disease-related complications [PDF]

, 2019
Primary myelofibrosis is a chronic clonal stem cell disorder that results in a build-up of marrow fibrosis and dysfunction, hypermetabolic states, and myeloid metaplasia.
Paiva, J, Singh, D, Noe, G, Oon, SF, Tan, TH, Burbury, K, Lee, A   +6 more
core   +1 more source

Development of Dermatomyositis in a Patient with Primary Myelofibrosis

Hematology, 2001
It is known that immunologic mechanisms play an important role in the disease process of some patients with idiopathic myelofibrosis. Patients with idiopathic myelofibrosis have an increased incidence of autoantibodies and circulating immune complexes.
TAŞKAPAN, HÜLYA, Gürsoy, S., Oymak, O., ÇETİN, MEHMET YAVUZ, Özbakir, Ö.   +4 more
openaire   +3 more sources

Epigenomic profiling of myelofibrosis reveals widespread DNA methylation changes in enhancer elements and ZFP36L1 as a potential tumor suppressor gene that is epigenetically regulated

Haematologica, 2019
In this study we interrogated the DNA methylome of myelofibrosis patients using high-density DNA methylation arrays. We detected 35,215 differentially methylated CpG, corresponding to 10,253 genes, between myelofibrosis patients and healthy controls ...
Nicolás Martínez-Calle, Marien Pascual, Raquel Ordoñez, Edurne San José Enériz, Marta Kulis, Estíbaliz Miranda, Elisabeth Guruceaga, Víctor Segura, María José Larráyoz, Beatriz Bellosillo, María José Calasanz, Carles Besses, José Rifón, José I. Martín-Subero, Xabier Agirre, Felipe Prosper   +15 more
doaj   +1 more source

Sirolimus is effective for paediatric Evans syndrome and secondary autoimmune cytopenias: A retrospective cohort study

British Journal of Haematology, EarlyView.
Maggie McNeill, Camilla Cellarius, Nethmi Illamperuma, Rachelle Zipper, Clarisse Carcao, Jillian M. Baker, Sheila Butchart, Michelle Fantauzzi, Caroline Malcolmson, Reena Pabari, Diandra Rollan, Kathleen Qu, Manuel Carcao   +12 more
wiley   +1 more source

Impact of Hemoglobin Improvement on Survival in Patients With Myelofibrosis and Anemia Treated With Momelotinib in the SIMPLIFY‐1 and MOMENTUM Trials

European Journal of Haematology, Volume 117, Issue 5, Page 1265-1274, November 2026.
In this post hoc analysis of the phase 3 SIMPLIFY‐1 and MOMENTUM trials, the number of patients with baseline hemoglobin < 10 g/dL who achieved hemoglobin ≥ 10 g/dL by week 24 with momelotinib, as well as the time to achievement, were evaluated. Patients who were JAK inhibitor naive and/or had moderate anemia were more likely and faster to achieve this
Francesca Palandri, Casey O'Connell, Pankit Vachhani, Donal P. McLornan, Steffen Koschmieder, Juan Carlos Hernandez‐Boluda, Kazuya Shimoda, Shiyuan Zhang, Catherine Ellis, Jessica Lim, Jasmine Sahni, Vikas Gupta   +11 more
wiley   +1 more source

NFкB pathway suppression as a key driver of pacritinib response in high‐risk myelofibrosis

British Journal of Haematology, EarlyView.
R. Van Dijck, M. ter Borg, B. van der Holt, A. E. C. Broers, M. D. Hazenberg, J. J. Cornelissen, N. P. M. Schaap, E. de Pater, P. A. W. te Boekhorst   +8 more
wiley   +1 more source

The Lupus Damage Index Revision Program: Results From the Item Generation and Reduction Phases

Arthritis Care &Research, Volume 78, Issue 10, Page 1449-1466, October 2026.
Objective A data‐driven and expert/patient consensus‐based project to develop a revised Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) Damage Index (SDI) is under way supported by SLICC, ACR, and the Lupus Foundation of America. Our objective is to report the item generation and reduction phase results
Burak Kundakci, Megan R. W. Barber, Ann E. Clarke, Sindhu R. Johnson, Anselm Mak, Hermine I. Brunner, Murat Inanc, Rosalind Ramsey‐Goldman, Guillermo Ruiz‐Irastorza, Ellen M. Ginzler, John G. Hanly, Alexandra Legge, Cynthia Aranow, Laurent Arnaud, Nathalie Costedoat‐Chalumeau, Dafna D. Gladman, Søren Jacobsen, Michelle Petri, Clovis A. Silva, Évelyne Vinet, Alexandre E. Voskuyl, SDI Revision Literature Review Groups, SDI Revision Delphi Panel, SDI Revision Item Reduction Committee, SDI Revision Clinical Domain Groups, Ian N. Bruce   +25 more
wiley   +1 more source

Childhood primary myelofibrosis presented with headache, splenomegaly, and severe thrombocytosis: A case report

Indian Journal of Medical and Paediatric Oncology, 2018
Primary myelofibrosis (PMF) is a clonal disorder of a multipotent hematopoietic progenitor cell that occurs predominantly in the elderly age group. We report here an 11-year-old girl who presented with headache, fever, and splenomegaly.
Athanasios Tragiannidis, Athanasia Apsemidou, Ioannis Liampas, Triantafyllia Koletsa   +3 more
doaj   +1 more source